PRMT5 inhibitors
Grant
US12595262B2
Kind: B2
Apr 07, 2026
Assignee
Merck Sharp & Dohme LLC
Inventors
Michelle Machacek, Michael D. Altman, Chunhui Huang, Michael H. Reutershan, David L. Sloman, David J. Witter, Craig R. Gibeau
Abstract
The present invention provides a compound selected from: compounds A, B, C, D and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutical compositions comprising compounds disclosed herein, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
CPC Classifications
C07D 487/04
C07D 401/14
C07B 2200/05
Filing Date
2020-12-14
Application No.
17787113
Claims
14